Zanubrutinib and Lenalidomide as Maintenance Therapy in DLBCL

NCT06503263 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

240

Enrollment

OTHER

Sponsor class

Conditions

Diffuse Large B-cell Lymphoma

Interventions

DRUG: Zanubrutinib plus Lenalidomide as Maintenance Therapy

Sponsor

Navy General Hospital, Beijing